Both METTL3 and METTL14 are downregulated in patients with type 2 diabetes, whereas FTO demonstrates an increased expression pattern, which enhances the expression of forkhead box O1 (FoxO1), glucose-6-phosphatase (G6PC), and diacylglycerol acyltransferase 2 (DGAT2) enzymes; this finally leads to hyperglycemia, due to insulin secretion dysregulation. Here, G6PC1 is linked to type 2 diabetes mellitus.